Pablo Berlanga Charriel: It is a pleasure to announce that the first results of the SACHA France study have recently been published.

Pablo Berlanga Charriel, Pediatric Oncology Consultant at Gustave Roussy, recently shared on LinkedIn:

“It is a pleasure to announce that the first results of the SACHA France study have recently been published: https://lnkd.in/e6ijeeXw Prospective collection of safety and activity data for compassionate or off-label innovative anticancer treatment in children, adolescents, and young adults in France is now a reality in ALL French Society of Pediatric Oncology (SFCE) centers!

This is just the beginning:
– SACHA France continues collaborating with the French National Agency for the Safety of Medicines and Health Products (ANSM) to ensure the adequate monitoring of all anticancer prescriptions to pediatric patients within compassionate use programs in France. Results were shared at the ASCO meeting this year: https://lnkd.in/eAfeh4y9
– SACHA France has been approved by the Haute Autorité de Santé (HAS) as real-world data source to respond to regulatory requests for early access programs (previous to marketing authorization) and post-registration studies in France: https://lnkd.in/epfTvXtC

Big thanks to the amazing SACHA France team, the French Society of Pediatric Oncology (SFCE) and participating patients and families. Many thanks to Imagine for Margo, Association Hubert Gouin – Enfance & Cancer and Fondation du LEEM for their funding support and to the ANSM and HAS for their precious support and collaboration.”

Source: Pablo Berlanga Charriel/LinkedIn